HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Efficacy of naftopidil for nocturia in male patients with lower urinary tract symptoms: comparison of morning and evening dosing.

AbstractOBJECTIVES:
To examine the difference in improvement of lower urinary tract symptoms between morning and evening dosing of α1 -blocker naftopidil.
METHODS:
A total of 177 male patients with nocturia were included in the present study and randomized to morning or evening dosing of naftopidil. The International Prostate Symptom Score, quality of life index and nocturia quality of life index were compared between the two study groups at 12 weeks.
RESULTS:
A total of 143 patients (morning group: n = 70, evening group: n = 73) were analyzed as a result of the dropout of 34 patients because of failure to give consent, adverse events and failure to attend. Nocturia, quality of life index and nocturia quality of life index at 12 weeks were significantly better in the evening group compared with the morning group. In a multivariate model, both the dosing time of naftopidil and the initial nocturia quality of life index were significantly associated with change in nocturia quality of life index.
CONCLUSIONS:
Evening dosing of naftopidil seems to be more effective in treating nocturia in male patients with lower urinary tract symptoms.
AuthorsTomoaki Tanaka, Katsuyuki Kuratsukuri, Rikio Yoshimura, Takahisa Adachi, Tetsuo Yamaguchi, Tetsuji Ohmachi, Shinji Yamamoto, Takahiro Nakamura, Satoshi Tamada, Tatsuya Nakatani
JournalInternational journal of urology : official journal of the Japanese Urological Association (Int J Urol) Vol. 22 Issue 3 Pg. 317-21 (Mar 2015) ISSN: 1442-2042 [Electronic] Australia
PMID25421868 (Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial)
Copyright© 2014 The Japanese Urological Association.
Chemical References
  • Adrenergic alpha-Antagonists
  • Naphthalenes
  • Piperazines
  • naftopidil
Topics
  • Adrenergic alpha-Antagonists (administration & dosage)
  • Aged
  • Aged, 80 and over
  • Humans
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Naphthalenes (administration & dosage)
  • Nocturia (drug therapy)
  • Piperazines (administration & dosage)
  • Prostatic Hyperplasia (complications)
  • Quality of Life
  • Time Factors
  • Treatment Outcome
  • Urodynamics

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: